1512 studies found for:    E1a11
Show Display Options
Rank Status Study
1 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
2 Active, not recruiting A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
Condition: Dengue Fever
Interventions: Biological: 4 µg TDENV-PIV with Alum adjuvant;   Biological: 1 µg TDENV-PIV with AS03B1 adjuvant;   Other: Phosphate buffered saline;   Biological: 1 µg TDENV-PIV with Alum adjuvant;   Biological: 1 µg TDENV-PIV with AS01E1 adjuvant
3 Completed ED50 and ED95 of Intrathecal Bupivacaine With or Without Epinephrine for Total Knee Replacement Arthroplasty
Conditions: Spinal Anesthesia;   Total Knee Replacement Arthroplasty
Interventions: Drug: intrathecal bupivacaine 6 mg with 100 mcg of epinephrine;   Drug: intrathecal bupivacaine 7 mg with 100 mcg of epinephrine;   Drug: intrathecal bupivacaine 8 mg with 100 mcg of epinephrine;   Drug: intrathecal bupivacaine 9 mg with 100 mcg of epinephrine;   Drug: intrathecal bupivacaine 10 mg with 100 mcg of epinephrine;   Drug: intrathecal bupivacaine 11 mg with epinephrine 100 mcg;   Drug: intrathecal bupivacaine 6 mg with 200 mcg of epinephrine;   Drug: intrathecal bupivacaine 7 mg with 200 mcg of epinephrine;   Drug: intrathecal bupivacaine 8 mg with 200 mcg of epinephrine;   Drug: intrathecal bupivacaine 9 mg with 200 mcg of epinephrine;   Drug: intrathecal bupivacaine 10 mg with 200 mcg of epinephrine;   Drug: intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
4 Completed Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: AdGVPEDF.11D
5 Completed
Has Results
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
Condition: Meningococcal Disease
Intervention: Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
6 Terminated
Has Results
Alprostadil in Maculopathy Study (AIMS)
Condition: Macular Degeneration
Interventions: Drug: Alprostadil (prostaglandin E1);   Other: Placebo
7 Completed Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
Condition: Encephalitis, Tick-Borne
Intervention: Procedure: blood draw
8 Completed Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: vildagliptin
9 Completed Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Intervention: Biological: Serogroup B meningococcal vaccine
10 Completed
Has Results
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: FF/GW642444 Inhalation Powder;   Drug: GW642444 Inhalation Powder
11 Completed
Has Results
Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)
Condition: Osteoporosis
Interventions: Drug: Zoledronic Acid;   Drug: Placebo
12 Completed Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12
Conditions: Meningococcal Disease;   Meningococcal Meningitis
Interventions: Biological: rMenB+OMV NZ with routine vaccinations;   Biological: rMenB+OMV NZ;   Biological: two doses of rMenB+OMV NZ
13 Active, not recruiting Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
Conditions: Submental Fat;   Healthy
Interventions: Drug: ATX-101;   Drug: Placebo
14 Recruiting Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28
Conditions: Meningoccocal Disease,;   Meningococcal Meningitis
Interventions: Biological: rMenB + OMV vaccine (1 dose at study month zero);   Biological: rMenB + OMV vaccine (2 doses 1 month apart)
15 Recruiting Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors
Condition: Disseminated Malignant Melanoma, Advanced Solid Tumors
Intervention: Biological: AdCD40L
16 Active, not recruiting Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Secukinumab Phase III Studies
Condition: Moderate to Severe Chronic Plaque-Type Psoriasis
Intervention: Drug: AIN457
17 Completed An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits
Condition: Traumatic Brain Injury With Persistent Cognitive Deficits
Intervention: Drug: Rivastigmine
18 Unknown  Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Conditions: Adenocarcinoma of the Colon;   Stage III Colon Cancer
Interventions: Drug: irinotecan hydrochloride;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Biological: cetuximab
19 Completed Immunogenicity and Safety of V70P5 Revaccination Subjects
Condition: Influenza
Intervention: Biological: Adjuvanted seasonal influenza vaccine
20 Recruiting Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: idarubicin hydrochloride;   Drug: vorinostat;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years